RPL7A Antibody - #DF9137

Fig. 1 SOX1 decreases ribosome pathway and DNA replication in NPC cells. A An experimental timeline for doxycycline (Blue block: 0 µg/ml, red block: 1 µg/ml) schedules used to control the expression of SOX1 in cells (HONE1 TRE-SOX1 or CNE2 TRE-SOX1). On day 2 and day 4, the cells were counted and proteins were extracted for protein concentration and western blot analysis, respectively. B Western blot analysis of SOX1, RPS3, RPL7A, and β-actin expression in cells. β-actin was used as a control. C Gene set enrichment analysis (GSEA) of ranked genes from cells. Gene set “hsa03010: Ribosome” of KEGG pathways was presented. NES normalized enrichment score. D Scatter dot plots showing the average protein content per cell. E An experimental timeline for doxycycline (Blue block: 0 µg/ml, red block: 1 µg/ml) schedules used to control the expression of SOX1 in cells (HONE1 TRE-SOX1 or CNE2 TRE-SOX1). Both groups of cells were treated with 20 µM BrdU for varying durations, and on day 4, BrdU-positive cells were determined by flow cytometry analysis. F Histograms showing the percentage of BrdU-negative or -positive cells in “SOX1-High” and “SOX1-Low” groups of cells. G Time courses of the percentage of BrdU-positive cells in BrdU incorporation assays, which were fitted by an exponential plateau equation. H An illustration of model hypothesis that overexpression of SOX1 induces quiescent NPC cells. Dox Doxycycline.